Isabelle Mohr
Heidelberg University
17 Papers
23 Citations
Isabelle Mohr is an academic researcher from Heidelberg University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Biochemical Markers for the Diagnosis and Monitoring of Wilson Disease.
Isabelle Mohr,Karl Heinz Weiss +1 more
- 01 May 2019
TL;DR: The following review focuses especially on biochemical markers and how they can be utilised in diagnosis and drug monitoring.
54
Excessive copper impairs intrahepatocyte trafficking and secretion of selenoprotein P
Maria Schwarz,Alina Löser,Kristina Lossow,Julian Hackler,Christian Ott,Susanne Jäger,Isabelle Mohr,Angana A. H. Patel,Nadia Gul,Samantha Alvarez,Clotilde Wiel,Maria Henrietta Maares,Hajo Haase,Anetta Härtlová,Tilman Grune,Matthias B. Schulze,Tanja Schwerdtle,Uta Merle,Hans Zischka,Volkan I. Sayin,Lutz Schomburg,Anna P. Kipp +21 more
TL;DR: In this paper , the authors show that copper treatment increased intracellular selenium and SELENOP in hepatocytes and decreased extracellular SELOP levels, indicating a disrupting effect of excessive copper on SELOPE transport in the late Golgi.
The MBOAT7 rs641738 variant is associated with an improved outcome in primary sclerosing cholangitis
Cora Freund,Arne Wahlers,Nima Haji Begli,Yvonne Leopold,Petra Klöters-Plachky,Arianeb Mehrabi,Isabelle Mohr,Julia Sander,Christian Rupp,Daniel Gotthardt,Karl Heinz Weiss +10 more
TL;DR: Unlike other chronic liver diseases, carrying two MBOAT7 variant alleles does not seem to affect PSC patients negatively, but seems to have a positive effect on transplant-free survival.
14
Neurological worsening in Wilson Disease - Clinical classification and outcome.
Isabelle Mohr,Jan Pfeiffenberger,Ece Eker,Uta Merle,Aurélia Poujois,Aftab Ala,Karl Heinz Weiss +6 more
TL;DR: In this paper , the authors characterized the occurrence, associated outcomes and potential reversibility of neurological worsening (NW) in patients with Wilson disease under therapy and identified two peaks in NW: an early (≤3 months) treatmentassociated peak and a late (>12 months of treatment) adherence-associated peak.
12
An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma.
Max Sauter,Philipp Uhl,Kathrin I. Foerster,Isabelle Mohr,Rahel T. Höne,Uta Merle,Jürgen Burhenne,Walter E. Haefeli +7 more
TL;DR: The UHPLC-MS/MS assay was successfully used for the determination of trough plasma concentrations of two patients with Clostridium difficile infection receiving oral vancomycin therapy and its performance was compared to a commercial immunoassay for concentrations close to its LLOQ.
11